– UK, Oxford – Vaccitech Ltd., a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced the appointments of Dr. Anne Phillips and Karen Dawes to its Board as independent directors, effective on 17 February 2021
Their appointments add strong independent perspectives on drug development and commercialization to Vaccitech’s Board.
“Anne and Karen are truly exceptional and accomplished additions to the Board,” said Board Chairman, Robin Wright. “Vaccitech will be able to draw on their deep knowledge of clinical development and commercialization to improve its prospects for rapid growth and development. Also, the breadth of their experience in the healthcare sector means that they will each be able to bring considerable wisdom to the Board as a whole. We welcome Anne and Karen to Vaccitech and look very much forward to their contributions.”
About Dr. Anne Phillips
Dr. Phillips has extensive biopharmaceutical product development experience. She currently serves as Senior Vice President Clinical, Medical & Regulatory Affairs at Novo Nordisk, where she has overseen more than a dozen FDA drug approvals. Before this, she served in multiple executive roles in drug development at GlaxoSmithKline including Vice President Medicine Development Leader of a leading prostate cancer therapeutic. Before building a long career in the pharmaceutical industry, Dr. Phillips served as Head of Infectious Diseases programs and Deputy Physician-in-chief at Wellesley Central Hospital/St. Michael’s Hospital in Toronto, Canada. Dr. Phillips is based in the USA.
“Vaccitech’s ChAdOx-MVA immunotherapy platform induces robust CD8+ T cell responses, which differentiates it from other immunotherapy platforms,” said Dr. Phillips. “The Company is developing candidates that target significant medical needs in oncology and infectious disease and which have the potential to improve patients’ lives.”
About Karen Dawes
Ms. Dawes has led a distinguished career as an executive at several biopharmaceutical companies including Bayer Corp., Wyeth Pharmaceuticals, Genetics Institute, and Pfizer, where she held leadership roles in business, marketing, and commercialization. More recently, Ms. Dawes has led her own successful consultancy company working with emerging companies on corporate strategy and commercial development. Since 2005, Ms. Dawes has served on the boards of several public and private biopharmaceutical companies, and she continues to serve on the boards of Repligen Corp., Medicines 360, Medicenna Therapeutics, and PaxMedica Therapeutics. Ms. Dawes is also based in the USA.
“Vaccitech is an exciting company with both therapeutic and prophylactic candidates in clinical development in oncology and infectious disease. The Company’s platform technology provides the opportunity to generate many more candidates in the future,” said Ms. Dawes. “I look forward to working with my new colleagues on the Vaccitech Board and with the management team to advance these programs through clinical development and toward commercialization.”
About Vaccitech Ltd.
Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The company’s proprietary platform comprises proprietary modified simian adenoviral vectors, known as ChAdOx1 and ChAdOx2, as well as the well-validated Modified Vaccinia Ankara, or MVA, boost vector, both with demonstrable safety profiles and without the ability to replicate in humans. The combination of a ChAdOx prime treatment with subsequent MVA boost has consistently generated significantly higher magnitudes of CD8+ T cells compared with other technologies and approaches. The company has a broad pipeline of both clinical and preclinical stage therapeutic programs in solid tumors and viral infections and prophylactic viral vaccine programs. Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI. Vaccitech is entitled to receive a share of the milestones and royalty income received by OUI from AstraZeneca.
For more information: https://www.vaccitech.co.uk/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
